JUNS insider transaction filings
JUPITER NEUROSCIENCES, INC. — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen JUNS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 7 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Hayward Marshall A. — Chief Scientific Officer, Director | 1 | — | — | 6 |
| Rosen Alexander Gustaf Erik — Chief Administrative Officer | 1 | — | — | 4 |
| Hemmerly Nicholas H. — Director | 1 | — | — | 2 |
| Kampf Julie B. — Director | 1 | — | — | 2 |
| Weis Holger — Director | 1 | — | — | 2 |
| Cutler Andrew Jon — Director | 1 | — | — | 1 |
| Philipson Tomas Jan — Director | 1 | — | — | 1 |
Recent Form 4 filings — JUPITER NEUROSCIENCES, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | Cutler Andrew Jon — Director | Grant/award (A): 472,222 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Kampf Julie B. — Director | Option exercise (M): 82,875 · Option exercise (M): 82,875 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Rosen Alexander Gustaf Erik — Chief Administrative Officer | Option exercise (M): 164,553 · Option exercise (M): 96,608 · Option exercise (M): 164,554 (derivative) @ $0 · Option exercise (M): 96,608 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Hayward Marshall A. — Chief Scientific Officer, Director | Option exercise (M): 389,793 · Option exercise (M): 399,402 · Option exercise (M): 225,000 · Option exercise (M): 389,793 (derivative) @ $0 · Option exercise (M): 399,402 (derivative) @ $0 · Option exercise (M): 225,000 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Hemmerly Nicholas H. — Director | Option exercise (M): 95,550 · Option exercise (M): 95,550 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Weis Holger — Director | Option exercise (M): 85,800 · Option exercise (M): 85,800 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Philipson Tomas Jan — Director | Grant/award (A): 536,428 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Brady Allison W — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Elmasri Saleem — Chief Financial Officer | Grant/award (A): 525,565 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | ROSEN CHRISTER — CEO and Chairman, Director | Grant/award (A): 747,783 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Hemmerly Nicholas H. — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kampf Julie B. — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Silva Alison D. — President and COO, Director | Grant/award (A): 1,027,304 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Hayward Marshall A. — Chief Scientific Officer, Director | Grant/award (A): 259,231 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Weis Holger — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Rosen Alexander Gustaf Erik — Chief Administrative Officer | Grant/award (A): 341,843 (derivative) @ $0 | EDGAR |
| 2025-07-07 | 4 | Elmasri Saleem — CFO and Secretary | Option exercise (M): 66,293 @ $0 · Grant/award (A): 102,128 (derivative) | EDGAR |
| 2025-07-07 | 4 | Silva Alison D. — Pres + Chief Business Officer | Grant/award (A): 255,320 (derivative) | EDGAR |
| 2025-07-03 | 4 | Silva Alison D. — Pres + Chief Business Officer, Director | Purchase (P): 250 @ $1.03 · Purchase (P): 250 @ $1.03 · Purchase (P): 250 @ $1.03 | EDGAR |
| 2025-07-03 | 4 | ROSEN CHRISTER — CEO and Chairman, Director, 10% owner | Purchase (P): 500 @ $1.01 · Purchase (P): 3,100 @ $1.02 | EDGAR |
| 2025-07-01 | 4 | Silva Alison D. — Pres + Chief Business Officer, Director | Option exercise (M): 110,227 @ $0 · Purchase (P): 250 @ $1 · Purchase (P): 100 @ $1.03 · Purchase (P): 250 @ $1.04 · Purchase (P): 250 @ $1.05 · Purchase (P): 100 @ $1.02 · +4 more | EDGAR |
| 2025-07-01 | 4 | ROSEN CHRISTER — CEO and Chairman, Director, 10% owner | Option exercise (M): 497,396 @ $0 · Option exercise (M): 476,070 @ $0 · Purchase (P): 166 @ $1.06 · Purchase (P): 1,000 @ $0.98 · Purchase (P): 2,000 @ $1.01 · Purchase (P): 1,450 @ $1.02 · +3 more | EDGAR |
| 2025-01-24 | 4 | Weis Holger — Director | Option exercise (M): 10,781 · Option exercise (M): 10,781 (derivative) @ $2.80 | EDGAR |
| 2025-01-24 | 4 | Brady Allison W — Director | Option exercise (M): 21,750 · Option exercise (M): 21,750 (derivative) @ $2.80 | EDGAR |
Recent 8-K events — JUPITER NEUROSCIENCES, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-03 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-28 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-28 | 8-K | 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=JUNS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →